公开(公告)号：US20240299680A1

公开(公告)日：2024-09-12

申请号：US18669046

申请日：2024-05-20

Applicant: Belhaven BioPharma Inc.

Inventor： Scott Lyman ,  Barry Bleske

IPC: A61M15/08 ,  A61K9/00 ,  A61K9/16 ,  A61K31/13 ,  A61K31/137 ,  A61K31/277 ,  A61K31/417 ,  A61K31/4425 ,  A61K31/46 ,  A61K31/55 ,  A61K31/5513

CPC classification number: A61M15/08 ,  A61K9/0043 ,  A61K9/1611 ,  A61K9/1623 ,  A61K9/1652 ,  A61K31/13 ,  A61K31/137 ,  A61K31/277 ,  A61K31/417 ,  A61K31/4425 ,  A61K31/46 ,  A61K31/55 ,  A61K31/5513 ,  A61M2205/3327 ,  A61M2209/06

Abstract: Provided herein are dry powder formulations comprising at least one active pharmaceutical ingredient suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including respiratory conditions, hemodynamic collapse, seizures, migraines, and other conditions.

公开(公告)号：US12102629B1

公开(公告)日：2024-10-01

申请号：US17929538

申请日：2022-09-02

Applicant: Belhaven BioPharma Inc.

Inventor： Barry Bleske ,  Ted William Lanpher

IPC: A61K31/46 ,  A61K9/00 ,  A61K31/137 ,  A61K31/4425 ,  A61K31/5513 ,  A61M15/00 ,  A61M15/08

CPC classification number: A61K31/46 ,  A61K9/0043 ,  A61K9/0075 ,  A61K31/137 ,  A61K31/4425 ,  A61K31/5513 ,  A61M15/0065 ,  A61M15/08 ,  A61M2202/064

Abstract: Nasally targeted dry powder compositions and methods for their use in the treatment of exposure to organophosphate compounds including chemical warfare agents and pesticides. Compositions include anticholinergic agents and cholinesterase reactivator agents used for primary treatment and vasoactive agents and benzodiazepines used for secondary treatment of exposure, and combinations of these agents. Compositions incorporate excipients and enabling agents such as permeation enhancers, and optimal sizing of active pharmaceutical ingredient particle size to improve drug delivery across the nasal mucosa, stability, and resistance to heat degradation. Packaging and configuration of devices for dry powder nasal compositions enable their use by non-medical personnel in civilian mass casualty or battlefield environments.

公开(公告)号：US20220395457A1

公开(公告)日：2022-12-15

申请号：US17836588

申请日：2022-06-09

Applicant: Belhaven BioPharma Inc.

Inventor： Scott Lyman ,  Barry Bleske ,  Ted William Lanpher

IPC: A61K9/00 ,  A61K47/26 ,  A61K47/38 ,  A61K31/137 ,  A61K31/417 ,  A61K31/277 ,  A61K47/02

Abstract: Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

公开(公告)号：US12005185B2

公开(公告)日：2024-06-11

申请号：US18082311

申请日：2022-12-15

Applicant: Belhaven BioPharma Inc.

Inventor： Scott Lyman ,  Barry Bleske

IPC: A61M15/08 ,  A61K9/00 ,  A61K9/16 ,  A61K31/13 ,  A61K31/137 ,  A61K31/277 ,  A61K31/417 ,  A61K31/4425 ,  A61K31/46 ,  A61K31/55 ,  A61K31/5513

CPC classification number: A61M15/08 ,  A61K9/0043 ,  A61K9/1611 ,  A61K9/1623 ,  A61K9/1652 ,  A61K31/13 ,  A61K31/137 ,  A61K31/277 ,  A61K31/417 ,  A61K31/4425 ,  A61K31/46 ,  A61K31/55 ,  A61K31/5513 ,  A61M2205/3327 ,  A61M2209/06

Abstract: Provided herein are dry powder formulations comprising at least one active pharmaceutical ingredient suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including respiratory conditions, hemodynamic collapse, seizures, migraines, and other conditions.

公开(公告)号：US20240148990A1

公开(公告)日：2024-05-09

申请号：US18417683

申请日：2024-01-19

Applicant: Belhaven BioPharma Inc.

Inventor： Scott Lyman ,  Brian Taubenheim ,  Anthony Hickey

IPC: A61M15/08 ,  A61K31/137 ,  A61K47/36 ,  A61M15/00

CPC classification number: A61M15/08 ,  A61K31/137 ,  A61K47/36 ,  A61M15/008 ,  A61M2202/064 ,  A61M2205/3553 ,  A61M2205/3584 ,  A61M2205/502 ,  A61M2209/06 ,  A61M2210/0618

Abstract: Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

公开(公告)号：US11617716B2

公开(公告)日：2023-04-04

申请号：US17836588

申请日：2022-06-09

Applicant: Belhaven BioPharma Inc.

Inventor： Scott Lyman ,  Barry Bleske ,  Ted William Lanpher

IPC: A61K9/00 ,  A61K47/26 ,  A61K47/02 ,  A61K31/137 ,  A61K47/38 ,  A61K31/417 ,  A61K31/277

Abstract: Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

公开(公告)号：US20250000792A1

公开(公告)日：2025-01-02

申请号：US18883447

申请日：2024-09-12

Applicant: Belhaven BioPharma Inc.

Inventor： Scott Lyman ,  Barry Bleske ,  Ted William Lanpher

IPC: A61K9/00 ,  A61K31/137 ,  A61K31/277 ,  A61K31/417 ,  A61K47/02 ,  A61K47/26 ,  A61K47/38

Abstract: Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

公开(公告)号：US20230240983A1

公开(公告)日：2023-08-03

申请号：US18192404

申请日：2023-03-29

Applicant: Belhaven BioPharma Inc.

Inventor： Scott Lyman ,  Barry Bleske ,  Ted William Lanpher

IPC: A61K9/00 ,  A61K31/137 ,  A61K45/06 ,  A61K31/417

CPC classification number: A61K9/0043 ,  A61K31/137 ,  A61K45/06 ,  A61K31/417 ,  A61K2300/00

Abstract: Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

公开(公告)号：US20230233460A1

公开(公告)日：2023-07-27

申请号：US18128705

申请日：2023-03-30

Applicant: Belhaven BioPharma Inc.

Inventor： Scott Lyman ,  Barry Bleske ,  Ted William Lanpher

IPC: A61K9/00 ,  A61K47/26 ,  A61K47/38 ,  A61K31/417 ,  A61K31/277 ,  A61K47/02 ,  A61K31/137

CPC classification number: A61K9/0075 ,  A61K47/26 ,  A61K47/38 ,  A61K9/0043 ,  A61K31/417 ,  A61K31/277 ,  A61K47/02 ,  A61K31/137

Abstract: Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

公开(公告)号：US12097287B2

公开(公告)日：2024-09-24

申请号：US18411663

申请日：2024-01-12

Applicant: Belhaven BioPharma Inc.

Inventor： Scott Lyman ,  Barry Bleske ,  Ted William Lanpher

IPC: A61K9/00 ,  A61K31/137 ,  A61K31/277 ,  A61K31/417 ,  A61K47/02 ,  A61K47/26 ,  A61K47/38

CPC classification number: A61K9/0075 ,  A61K9/0043 ,  A61K31/137 ,  A61K31/277 ,  A61K31/417 ,  A61K47/02 ,  A61K47/26 ,  A61K47/38

Abstract: Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.